Skip to content
Yog Pharma
CardiovascularAngiotensin-converting enzyme (ACE) inhibitor

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor indicated for hypertension, heart failure and acute myocardial infarction. We supply it to US manufacturers of tablets, oral solution and fixed-dose combinations.

CAS83915-83-7441.5 g/molC21H35N3O7
2D structure of Lisinopril, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 5362118) and FDA’s substance registry

CAS number

83915-83-7

Molecular formula

C21H35N3O7

Molecular weight

441.5g/mol

FDA UNII

IUPAC name

(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;dihydrate

InChIKey

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Appearance
White to off-white crystalline powder.
Solubility
Soluble in water, sparingly soluble in methanol and practically insoluble in ethanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Supplied as the dihydrate. The water content range and the limit for the diketopiperazine degradant are the figures to compare between sources.

On the US market

Reference product
ZestrilNDA 019777
Approved ANDAs
14 with a marketed product
Approved forms and strengths
  • Tablet 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
  • Oral solution 1 mg/mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com